Literature DB >> 32807301

GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach.

Beatriz Sicilia1, Santiago García-López2, Yago González-Lama3, Yamile Zabana4, Joaquín Hinojosa5, Fernando Gomollón6.   

Abstract

INTRODUCTION: Since the first edition of the Guidelines was published in 2013, much information has been generated around the treatment of ulcerative colitis, and new drugs and action protocols have been introduced. Clinical practice has changed substantially, warranting new approaches and a comprehensive review and update of the evidence.
MATERIAL AND METHODS: Once again, we used the GRADE approach, supported by an electronic tool (https://gradepro.org). The clinical scenarios are the same as in the previous version (induction and maintenance in severe and mild-moderate flare-ups), as are the variables and their evaluation. However, in the updated guidelines, three questions have been deleted, 14 added and 30 maintained, making a total of 44 clinical questions. After an exhaustive review of the evidence, the recommendations are now updated.
RESULTS: Of the 44 questions analysed, no recommendation could be established in two due to the very low quality of the evidence, while in the other 42, based on different degrees of quality of evidence, recommendations were made according to the GRADE system. In 25 of these questions the final recommendation is strongly in favour, in six strongly against, in seven weakly in favour and in four weakly against. According to the scenarios and recommendations, six algorithms are proposed as a simple guide for practical decision-making.
CONCLUSIONS: The aim of this update of the 2013 guidelines is to provide answers, based on the GRADE approach, to the different questions we ask ourselves daily when deciding the most appropriate treatment for our patients with ulcerative colitis in the different clinical scenarios.
Copyright © 2020. Publicado por Elsevier España, S.L.U.

Entities:  

Keywords:  Biological; Biológicos; Colitis ulcerosa; Corticoides; Corticosteroids; GRADE; Immunosuppressors; Inmunosupresores; Salicilatos; Salicylates; Tratamiento; Treatment; Ulcerative colitis

Mesh:

Year:  2020        PMID: 32807301     DOI: 10.1016/j.gastrohep.2020.07.001

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  5 in total

1.  Orally Deliverable Dual-Targeted Pellets for the Synergistic Treatment of Ulcerative Colitis.

Authors:  Xiaomeng Tang; Meng Yang; Yongwei Gu; Liangdi Jiang; Yue Du; Jiyong Liu
Journal:  Drug Des Devel Ther       Date:  2021-09-29       Impact factor: 4.162

2.  Polypharmacy in Patients With Inflammatory Bowel Disease: Prevalence and Outcomes in a Single-center Series.

Authors:  Francisco Mesonero; Cristina Fernández; Eugenia Sánchez-Rodríguez; Ana García-García Paredes; Carla Senosiain; Agustín Albillos; Antonio López-Sanromán
Journal:  J Clin Gastroenterol       Date:  2022-03-01       Impact factor: 3.062

Review 3.  How to Choose the Biologic Therapy in a Bio-naïve Patient with Inflammatory Bowel Disease.

Authors:  Viviana Laredo; Carla J Gargallo-Puyuelo; Fernando Gomollón
Journal:  J Clin Med       Date:  2022-02-04       Impact factor: 4.241

4.  Scientific Evidence of Chinese Herbal Medicine (Gegen Qinlian Decoction) in the Treatment of Ulcerative Colitis.

Authors:  Jinke Huang; Jiaqi Zhang; Yifan Wang; Jing Ma; Xuefei Yang; Xiaoxue Guo; Mi Lv; Jinxin Ma; Yijun Zheng; Fengyun Wang; Xudong Tang
Journal:  Gastroenterol Res Pract       Date:  2022-03-14       Impact factor: 2.260

Review 5.  Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era?

Authors:  Carla J Gargallo-Puyuelo; Viviana Laredo; Fernando Gomollón
Journal:  Front Med (Lausanne)       Date:  2021-07-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.